Skip to content

effect of collagenase enzyme in scleroderma

Evaluation of efficacy and safety of collagenase enzyme in the treatment of cutaneous sclerosis in patients with systemic scleroderma

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140624018210N11
Enrollment
17
Registered
2021-12-12
Start date
2022-01-05
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic scleroderma. Systemic sclerosis [scleroderma]

Interventions

Intervention group: The intervention group is patients suffering from scleroderma. The intervention group will use collagenase ointment topically, twice a day for three months without interruption. It

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients should have at least one active scleroderma lesion

Exclusion criteria

Exclusion criteria: Patients who have received or inhaled oral prostanoids in the past 3 months. Phosphodiesterase inhibitors have been used in the past month. Take antibiotics 2 weeks before the study.

Design outcomes

Primary

MeasureTime frame
Qualitative intensity of scleroderma. Timepoint: Before treatment and 3 months after treatment. Method of measurement: Patient complaint, objective evaluation by a physician.

Secondary

MeasureTime frame
Quantitative intensity of scleroderma. Timepoint: Before treatment, three months after treatment. Method of measurement: Determine the size of the lesions with visioface, determine the location and number of lesions.;The rate of improvement of scleroderma. Timepoint: Before treatment, three months after treatment. Method of measurement: Patient satisfaction, visioface photography, physician diagnosis.;Adverse events. Timepoint: Before treatment, three months after treatment. Method of measurement: Patient report, Physician diagnosis.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Elham. Behranghi

Iran University of Medical Sciences

elham.behranghi@gmail.com+98 21 6651 7341

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026